Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Neuroendocrine Carcinoma Therapeutics Market

P&S Market Research-Neuroendocrine Carcinoma Therapeutics Market report

Global Neuroendocrine Carcinoma Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10900
Available Format: pdf

Global neuroendocrine carcinoma therapeutics market is witnessing significant growth due to large number of marketed drugs and Phase III drugs. Neuroendocrine carcinoma is a tumor that begins in neuroendocrine cells and can spread, or metastasize, to other parts of the body. It starts in the hormone producing cells of the body’s neuroendocrine system. Neuroendocrine tumors can begin in many organs including, lungs, brain and gastrointestinal tract. It is a very rare cancer with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight loss, pain, cough, lump formation, jaundice, unusual bleeding, headache and anxiety. The risk factors of developing neuroendocrine cancer includes, age, gender, family history, immune system suppression, arsenic exposure and sun exposure. The diagnosis can be done by normal physical examination followed by blood tests, urine tests, X- ray, CT scan, PET scan, MRI and biopsy.

The treatments available for neuroendocrine tumor include chemotherapy, surgery and radiation therapy. Chemotherapy comprises the drug’s use to destroy malignant cells by hindering the cells ability to divide and grow. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some of the drugs that are used to treat neuroendocrine tumors. Many pharmaceutical companies have been working continuously for the development of targeted therapy for the growth of neuroendocrine cancer market.

Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for treatment of neuroendocrine cancer. Genentech Inc., F. Hoffmann-La Roche Ltd., Callisto Pharmaceuticals Pvt. Ltd. and BioSynthema, Inc. are some major companies that are determined to develop therapeutics for various neuroendocrine cancers. Lutathera, Atiprimod and Avastin are pipeline candidates that are presently being studied for their therapeutic efficacy in the treatment of neuroendocrine cancer. Also, there are many other pipeline drugs in Phase III which are expected to enter the neuroendocrine carcinoma therapeutics market in the future.

Geographically, neuroendocrine carcinoma therapeutics market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine carcinoma therapeutics market are based in the U.S and therefore consider North America as their main market for product launch and research and development investments. Also, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine carcinoma therapeutics market. Europe is the second largest market for neuroendocrine carcinoma therapeutics, followed by Asia. Increasing prevalence of neuroendocrine cancer in Asia Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

Some of the key players operating in the global neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen, Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

5100
Group License

Group License authorizes access of the publication upto 5 users.

6100
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

9100
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment